Journal
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
Volume 23, Issue 6, Pages 1193-+Publisher
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/j.hoc.2009.09.001
Keywords
ITP; Thrombopoietin; Thrombocytopenia; Platelets; TPO
Categories
Funding
- National Institutes of Health [HL82889, HL072299, HL072305]
Ask authors/readers for more resources
Since 1968, a greater understanding of platelet biology and its regulation by thrombopoietin (TPO) has emerged. It is now recognized that immune thrombocytopenic purpura (ITP) is a disorder of reduced platelet production as well as increased platelet destruction. New therapies for ITP have emerged that have exploited this new pathophysiologic understanding. This article reviews the biology of TPO, the regulation of its circulating level in ITP, the platelet kinetic data supporting inappropriate platelet production in ITP, and the TPO mimetic agents available to treat ITP.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available